Expert recommendations for Germany's integration of psychedelic-assisted therapy.

ABSTRACT: As clinical trials for psychedelics move into phase III in the USA, Europe must address its lag in integrating professional education around psychedelic-assisted therapy (PAT) and supporting psychedelic drug research. This paper evaluates the necessary frameworks for implementing PAT in Germany, emphasizing the nation's potential leadership role within the European Union. With Australia having already approved MDMA and psilocybin for mental health indications, the Ukrainian government exploring MDMA treatment for war-related PTSD, and initial clinical trials involving MDMA and LSD with patients in Switzerland which restarted the restricted medical use of these substances around 2014, the medical authorization of psychedelics in these countries establishes precedent showcasing both the prom

SUBMITTER: Perez Rosal SR 

PROVIDER: S-EPMC11515625 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature